Skip to main content
. 2021 Aug 31:aqab107. doi: 10.1093/ajcp/aqab107

Figure 1.

Figure 1

Antibody concentrations at t0 (before the prime vaccine dose; empty shape), t1 (after 21 days; lighter shapes), and t2 (15 days more; darker shapes) for each immunoassay: Maglumi SARS-CoV-2 S-RBD IgG (AU/mL), Atellica IM SARS-CoV-2 IgG (index), Elecsys Anti–SARS-CoV-2 S (U/mL), LIAISON SARS-CoV-2 TrimericS IgG (AU/mL), and Maglumi 2019-nCoV IgG (AU/mL). Data are represented in logarithm scale.